Last quarter (Q4 2022), Erytech Pharma SA's total revenue was €0.00, a decrease of ― from the same quarter last year. In Q4, Erytech Pharma SA's net income was €5.94M. See Erytech Pharma SA’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Total Revenue	-	€ 0.00	€ 0.00	€ 0.00	€ 0.00	€ 0.00
Cost of Revenue	-	-	-	€ 57.58M	€ 52.19M	€ 33.47M
Gross Profit	-	-	-	€ -57.58M	€ -52.19M	€ -33.47M
Operating Expense	€ 27.15M	€ 27.15M	€ 56.52M	€ 68.83M	€ 11.88M	€ 10.15M
Operating Income	€ -27.15M	€ -27.15M	€ -56.52M	€ -68.83M	€ -64.07M	€ -43.62M
Net Non Operating Interest Income Expense	€ 3.09M	€ 3.09M	€ 1.54M	€ -5.12M	€ 1.41M	€ 5.40M
Other Income Expense	€ -2.87M	€ 24.35M	€ 1.18M	€ 652.00K	-	-
Pretax Income	€ 293.00K	€ 293.00K	€ -53.80M	€ -73.30M	€ -62.66M	€ -38.22M
Tax Provision	€ 521.00K	€ 521.00K	€ 2.00K	€ 3.00K	€ -1.00K	€ 2.00K
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	€ -227.00K	€ -227.00K	€ -53.80M	€ -73.30M	€ -62.66M	€ -38.22M
Basic EPS	-	-	-	-	-	-
Diluted EPS	-	-	-	-	-	-
Basic Average Shares	-	-	-	-	-	-
Diluted Average Shares	-	-	-	-	-	-
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	€ 1.13M	€ 1.07M	€ 2.41M	€ 2.38M
Total Expenses	€ 27.15M	€ 27.15M	€ 56.52M	€ 68.83M	€ 64.07M	€ 43.62M
Net Income From Continuing And Discontinued Operation	€ -227.00K	€ -227.00K	€ -53.80M	€ -73.30M	€ -62.66M	€ -38.22M
Normalized Income	€ 1.49M	€ -14.84M	€ -54.66M	€ -73.77M	€ -62.66M	€ -38.22M
Interest Expense	€ 1.36M	€ 1.36M	€ 2.14M	€ 2.16M	€ 491.00K	€ 9.00K
EBIT	€ 1.66M	€ 1.66M	€ -51.66M	€ -71.14M	€ -62.17M	€ -38.22M
EBITDA	€ 1.66M	€ 1.66M	€ -46.28M	€ -66.14M	€ -57.95M	€ -37.42M

Currency in EUR

Erytech Pharma SA Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing